Welcome to the First Quarter 2025 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis. The presentation materials and additional financial tables are currently posted on the Investor Relations section of zoetis.com. The presentation slides can be managed by you, the viewer, and will not be forwarded automatically. In addition, a replay of this call will be available approximately two hours after the conclusion of this call via dial-in or on the Investor Relations section of zoetis.com. At this time, all participants have been placed in a listen-only mode and the floor will be open for your questions following the presentation. [Operator Instructions] It is now my pleasure to turn the floor over to Steve Frank. Steve, you may begin.

Thank you, operator. Good morning, everyone, and welcome to the Zoetis first quarter 2025 earnings call. I am joined today by Kristin Peck, our Chief Executive Officer, and Wetteny Joseph, our Chief Financial Officer. Before we begin, I'll remind you that the slides presented on this call are available on the Investor Relations section of our website, and that our remarks today will include forward-looking statements, and that actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements in today's press release and our SEC filings, including but not limited to, our annual report on Form 10-K and reports on Form 10-Q. Our remarks today will also include references to certain financial measures, which were not prepared in accordance with Generally Accepted Accounting Principles or US GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable US GAAP measures is included in the financial tables that accompany our earnings press release and the company's 8-K filing dated today, Tuesday, May 6th, 2025. We also cite operational results, which exclude the impact of foreign exchange. With that, I will turn the call over to Kristin.

Thank you, Steve, and welcome everyone to our first quarter 2025 earnings call. By staying laser-focused on delivering for our customers, our colleagues drove strong 9% organic operational revenue growth and grew adjusted net income 6% on an organic operational basis. Our International segment led with a 11% organic operational revenue growth, highlighting our global scale and diversification while the US grew 6%, excluding the impact of the MFA divestiture. Growth with balanced across species, our innovative companion animal portfolio grew 9% operationally, fueled by sustained demand for our diverse, market-leading franchises. Livestock grew 7% on an organic operational basis, driven by broad-based double-digit performance internationally. Before we go deeper into the quarter, I want to briefly address what is top of mind for many of you. In today's operating environment, the essential nature of our business remains clear, animals provide companionship and nourishment and in uncertain times people will rely on both. It's precisely because of the enduring secular trends and the fundamentals underpinning our innovation-led operating model. This is what it has consistently proven its resilience even through economic turbulence. That resilience is embedded in how we operate. From our global footprint and diverse durable portfolio across species and geographies, to our omni-channel presence, matrix manufacturing network and talented field force, combined those dynamics ensure for operating from a position of strength as we navigate a fluid environment shaped by macroeconomic, regulatory and geopolitical uncertainty. We are managing these challenges thoughtfully working to minimize their impact, while also seizing opportunities where they exist, so we can continue delivering for our customers, colleagues and shareholders. That means executing our strategy with discipline, supported by a strong balance sheet, operational, excellence thoughtful and strategic capital allocation and experienced leadership team ready to adapt as needed. Most importantly, we continue to…

Thank you, Kristin. In the first quarter, driven by balanced portfolio growth, we posted $2.2 billion in revenue, growing 1% on a reported basis and 9% on an organic operational basis, which excludes the impact of foreign exchange and the MFA divestiture. Our organic operational growth was driven by 4% price and 5% volume. Adjusted net income of $662 million grew 4% on a reported basis and 6% on an organic operational basis. Our companion animal portfolio led the way with $1.5 billion in revenue, growing 9% operationally. Globally and on an operational basis, our Simparica franchise contributed $367 million, growing 19%, key dermatology posted $387 million, growing 10%, and our OA pain mAbs reported $147 million, growing 15% in the quarter. Our Lifestyle portfolio also contributed organic operational growth of 7% on $645 million in revenue. Now moving on to our Q1 segment results. US revenue grew 2% on a reported basis and 6% on an organic operational basis in the quarter with companion animal growing 8% and livestock declining 2% on an organic operational basis. In companion animal, US growth was driven by our three key franchises, while vaccines faced headwinds from supply timing, coupled with competitor re-entry. Across the portfolio, alternative channel sales continued to outpace the vet channel, offering greater convenience for pet owners, improving compliance and stickiness. Driven by strong growth in auto ship programs that boost compliance and increase the lifetime value of each dog on treatment, our Simparica franchise posted 17% U S growth this quarter on $260 million in revenue. Additional competitive entrants are accelerating the market shift to triple combinations, where we continue to gain share, thanks to the strength of our field force, our first mover advantage and ongoing innovation, including expanded label claims. In key dermatology, sales were $249…

Thank you. [Operator Instructions] We’ll hear first from Erin Wright with Morgan Stanley. Please go ahead.

Great. Thanks. So, first on - I’ll do Librela first and then tariffs. I guess, you speak to what you’re seeing across the US market in terms of the Librela label change, how that’s responding relative to your expectations there? And how do you think the longer-acting OA pain product could potentially replace or enhance sort of the OA pain offering as we head into potentially next year? And then on tariffs, can you describe what exactly is embedded in terms of the growth tariff impact and what mitigation efforts you have? And then and then what does it mean when you say enacted tariffs? I guess, what tariff or jurisdictions are you incorporating or product categories, do you where do you have, I guess, the most exposure, and what sort of is the tariff impact now embedded in guidance? Thanks.

Sure. Thanks, Erin. I will take the Librela question. I’ll let Wetteny take the tariff question when I’m done. As we - as Wetteny sort of mentioned in his prepared remarks, we had about 15% organic operating growth in Librela across the globe with – and the US having about 17%. We are continuing to grow the market and vet satisfaction remains strong. Our focus right now is on building and scaling the new category of care and really focusing on continued education and engagement. Now that the label is settled, we’re really focusing on expanding our medical education. We’re investing in a number of post-launch studies as we’ve talked about to generate more real-world data. We’re also bringing in some key opinion leaders from Europe who’ve had the product for over five years to share their experiences in the US as well as investing in targeted DTC. So we continue to have long term confidence. It remains strong. And, you know, we really think Librela is meeting a significant unmet medical need and remain excited. Wetteny, do you want to, cover the tariff question?

Sure. Look, Erin, our guidance today reflects the net impact of the tariffs that are actually already in place and so that’s net of any mitigations that we’ve already put together, here although the situation remains fluid. To give you a little bit more color in terms of where the exposure is and what we have reflected today, just primarily from imports related to APIs, for a few of our livestock products coming from China. And then, some impact from few of our diagnostics products, as well as certain veterinary accessories. Zooming out, the situation remains fluid, obviously and we continue to monitor as well as are actively planning various scenarios depending on where tariffs land. Keep in mind, we have a broad diversity of geographic footprint and 60% of our manufacturing footprint is actually in the US. So I mean, we export more out of the US than we import into the US and particularly, when you think about companion animal, vast majority of our sales are actually produced in the US for those and a good portion of the companion animal sales outside the US are actually produced in the US. And so I think when you think about that, our exposure is really likely more from retaliatory tariffs from other jurisdictions. So most of our exports go to Europe as well as our imports are actually coming from Europe. So you think about that in the context. And, course, we continue to monitor those. Given our supply chain as broad as it is, that gives us lots of mitigation opportunities. So we until we know exactly where tariffs land, we won’t know exactly how much we’ll mitigate, but we do feel confident that our footprint allows us quite a bit of flexibility to do that. Those will range in terms of time frame where they can be executed, from immediate where it may be moving our inventories all the way to longer term in terms of what does that mean in terms of our footprint. So, lots of opportunities for us as we look at that, but given our diversity from a geography product, et cetera, standpoint, we feel we are as well positioned to navigate this as anyone else.

We’ll hear next from Michael Ryskin with Bank of America. Please go ahead.

Great. Thanks for taking the question guys. I’ll start on the competitive side of things. I think, Wetteny and Kristin, you guys both called out competitive entrants a little bit more in your prepared remarks. Obviously, you’ve had NexGard Plus in the market for a while now and also Credelio, Quattro and Zenrelia. Just if you could dive into a little bit more of like where are you seeing the most competitive pressure? How is it taking shape? Is it more in terms of price? Anything you are seeing in terms of pre-stocking, pre-selling? There’s a derm competitor expected later this year, as well. So just sort of what have you seen so far? What are you factoring into your guide from the competitive side of things in those categories? And then a follow-up on Librela, on Erin’s question there. I just want to - now that you’ve had the label change and some of the learnings from the last couple of months, is your assumption for fiscal year ’25 Librela any different than it was before? Do you think you’ll be able to offset some of these as you go through the year? Just wondering if your thoughts on the ramp for this year are any different than they might have been three months ago? Thanks.

Okay, great. I’ll start on the competitive side and then let Wetteny build off of it. I mean, I think what’s really important to note in both dermatology and parasiticides is we were the first mover and I think that’s really important because especially if you look at parasiticides, being the first mover made a big difference. Really, we’ve just been growing our share over time as we talked about. We obviously had one of the biggest competitors enter over a year ago and we’re printing 19% growth overall for the quarter in in Trio. So I think that’s incredibly strong. I think what we’re really seeing is that, there’s still 40% growth in a combined flea chick heartworm space and the more people that enter, the more people get switched into combo therapies from single therapies or topicals or collars. So, we continue to see that regardless of who is entering. We have an excellent product. It’s continued to compete really well in the market. We’re really proud of the execution on this in the US and around the globe. So, we’ve seen competition. We’re obviously going to continue to see more competition. I think what’s also something to focus on is that right now, we have a 40% share in puppies. And obviously, once one dog goes on a product, it’s, rare that it’ll switch. So I think that’s a really good indication of where that’s going in the future. As we talked about, we are expecting potentially a new competitor in dermatology. What you can get into the specifics, that’s baked in. But again, I’d say, you know, if you look at dermatology, we have three excellent products that have been in the market for a long time that are accepted that that have an over 90% satisfaction rate with those products and we are the first mover. So I’ll let Wetteny talk about what that means in guidance, et cetera, and then if you want to follow-up anything else on the Librela if you want, Wetteny.

Sure. If you look across our three key franchises and I think this will cross over both your first question on competitive entrants as well as, your question on Librela and I’ll double click on that a little bit, Mike. So first of all, our large three key franchises, we expect to grow double-digits, in 2025. They delivered 14% in the first quarter and remain double-digits in our guidance. I think if you look at these areas, including those that already have competition or where we expected we expect more entrants to come in. The bigger picture is the opportunity that remains I think in every area, you have large markets even at the current sizes. In derm, we still have $20 million that are undertreated or untreated. And clearly, with double-digit growth, in that category, a decade plus later, we’re accessing, those expansion opportunities and we have more to go, particularly when you think about international. If you look at Librela, again, our key franchises are double-digit expectations for the year. We haven’t given specific guidance consistently with the first guidance in February on a particular product. But I think I would share this. We had a very strong launch to this product in terms of penetration in clinics in the US, et cetera. If you look at that, that’s a strong foundation for us and really you look at the feedback from vet, they remain very strong in terms of satisfaction. And so, with twenty 27 million medicalized dogs in the US alone with OA and only 9 million being treated, 8 million lives on NSAIDs and 1 million on Librela, I don’t think I need to spell out just how vast the opportunity is and we’re still early. And clearly, as the adoption curve is lower than we expected, as we said in the prepared commentary, we are doubling down on efforts to drive education and awareness, et cetera. The industry has seen this before with other products. We’ve seen this before and we’re confident in terms of the long-term opportunity here and our position in it as a first mover and the impact it’s making on dogs across the world. So we’ll continue to drive those.

And the other thing I’d say is, we’re really seeing this as a huge market opportunity of the future. We’ve talked for a while that we think the overall market opportunity for us in a way is between $2 billion and $3 billion and we’re investing, as you know in a long-acting, o a monoclonal antibody that as we mentioned earlier in the year, we are expecting approval for this year. This would be a long-acting three month injection. It was a new and different antibody than Librela with the unique binding site and we’re expecting the dosing range to be about 10 times lower than Librela. So, obviously, we have a lot of confidence in continuing to grow this market and the potential for this market given all the things that Wetteny said and we’ll continue to invest in life cycle innovation behind Librela, as well.

We’ll hear next from Jon Block with Stifel. Please go ahead.

Great. Thanks, guys. Good morning. Hope you can hear me okay. Maybe just building on a couple of the prior questions, Wetteny just pretty straightforward, but can you just maybe help us and bridge us to the $0.20 increase to the 2025 EPS guidance, because just, obviously back of the envelope. But even with the advantageous move in FX, the lower interest expense, and the lower shares, I’m actually having a hard time getting to $0.20 and that’s arguably before any tariff headwind. I don’t know if you can give us like, a gross, or, net tariff impact on that side of the equation. And then, Kristin, I guess, just a little bit more on Librela. Pretty direct question, do we assume or should we assume flat US Librela revenue for the next two to three quarters until the long-acting is out there? I think the targets here in ‘25, give or take. Is there anything called in the near-term to reaccelerate the US Librela revenues before the long-acting? And then I know you just gave some helpful information on the long-acting. Is that going to carry, call it, a different brand versus Librela? Thanks guys.

Yeah. Sure. Look, John, I’ll take the bridge to the EPS raise, in dollars for you. If you go back to our initial guidance in February, which used rates, from late January versus where rates are as of late April. We are seeing initially what we, guided to was about a $200 million headwind related to FX on a reported basis and that was really reflective of the dollar that strengthened, particularly in the second half of 2024. If you look at where rates are at the April, largely driven two-thirds of this change is driven by the euro, the pound sterling and the yen, you are looking at most of that, not all of it, nearly all of it actually, being reversed with the weakening dollar. So that is largely, if not entirely, what’s driving the EPS change that you see from us driven by FX and I would tie this also with trade policy and tariffs and so on. So we talk a lot about the impact that has on the organic operational, but it does have somewhat of the opposite effect in terms of what is going to the dollar and demand for that. So I do want to make sure that that is at least looked at and recognized. And so, the impact you see is here. Now in terms of tariffs, net of mitigations, we’re calling about $20 million of headwind that we’re putting here and keep in mind, in February, we said we did not reflect tariffs and we would do so as we know more. And based on what’s enacted, we have that reflected here today, but for that, our organic operational growth in adjusted net income would be the same as it was in February. Again, I’ll give you a little bit more color in terms of what that impact is and I gave you some more in terms of where how we’re positioned as we continue to monitor the situation and where we have mitigation opportunities, as we look ahead. Hopefully, that helped in terms of the FX. I do think what you’re going to see is it’s flat - near flat for the year now with headwinds in the first half and tailwinds in the second half based on where rates are. Again, we don’t forecast the rates. We’re simply using the spot rates as of late April and assume they stay where they are, which we know they won’t. This would be the impact. And so that is consistently how we have reflected on FX.

So I’ll follow-up with your question with regards to Librela. I mean, as you know, we obviously don’t give quarterly guidance. But as I mentioned earlier, we are obviously investing to continue to grow and scale this product throughout the year. We’re doing all the things we mentioned obviously, the medical education, the DTC, we’re obviously investing in many post-launch studies to generate real-world data. You saw a few of those come out right now. We provided our pharmacovigilance data to Frontier’s journal, which indicated that all individual events are both rare and very rare. We also did a Librela meloxicam, which had 17 AEs for meloxicam and four for Librela. We’re continuing to invest in additional real-world studies to support the brand. So we are investing, obviously, to grow this brand. We are not waiting for growth until we get a long-acting monoclonal antibody. And I think you also said it will obviously have a different brand. It is a unique antibody and so obviously, therefore cannot share the brand of Librela given its unique molecule. So that would not have the same branding. But look, we can - I just want to reiterate, this is a $2 billion to $3 billion market. We are only $1 million right now on the product. There’s $9 million treated in the United States. But I’d argue, by the way, there’s 27,000,000 dogs with OA. So beyond even what’s treated today, there’s an untreated, market as well, so as you look at this. So we see this as a significant opportunity that we’re going to continue to invest behind.

We’ll take our next question from David Westenberg with Piper Sandler. Please go ahead.

Hi. Thanks. I’m going to actually get away from the Librela questions. So, Amazon is, now selling some of the online drugs probably, I think it’s just singles right now, but maybe get a broad spectrum. Can you talk about any changes in your sales or sales and marketing efforts, both in terms of educating vets or direct-to-consumer strategies? And with Amazon, do you see an acceleration of trends through the alternative channel? Or do you think this is just maybe more market share taking and it would just see the same exact acceleration or the same exact trends we’ve seen? And then, just a really quick one on the FDA and particularly the CMB. Can you tell whether or not there is any potential backlogs or delays in the FDA? I know that the actual reviewers, there hasn’t been any cuts in order to that. But I mean, I think there would be some maybe in some of the support staff that might have like maybe a downstream effect. Thank you.

Sure. I’ll start with your second question first. Yes, we are obviously monitoring any changes to both FDA and USDA closely. There are obviously work cuts, already at FDA, but we have not seen any slowdowns on any of our pipeline products as we talked about. We have a very robust pipeline. We work very closely with the FDA. And look, we’re working very closely with the administration, with Congress and with the regulators to help shape that evolving environment. We’re looking for opportunities to support their efforts on efficiencies, while supporting innovation. We think there is lots of opportunities to speed innovation and I’ve spent a lot of time in DC working with them. We really think that innovation is critical as you think about the food supply chain, as well as public health, as well as really bringing unmet products to market. So, it’s a real focus of ours here. We have not seen any slowdown in any of our pipeline products currently at the FDA or the USDA, but we are spending a lot of time there making sure we continue to shape this environment. The second question was on retail growth. I’ll start there and see what Wetteny has got to build on it. First, I’d underscore that retail in the quarter grew 40%. That was, you know, obviously, there’s a little bit there on some one-time stocking, so Wetteny can get into that. But right now, retail is 21% of our US business and this has been growing every year. So I mean, I think Amazon just one more. But Wetteny, do you want to get into some of the specifics there?

Yeah, I’d be happy to. I think to your point, if you look at retail and when we talk about alternative channels, we have both retail and home delivery, which we’re seeing traction there, as well. If you look at our retail in the quarter about 40% growth. Some of that as we talked about, in February, we saw a little bit of inventory decrease at the end of December through the holiday season. Some of that picked back up in January. So a little bit crossing over there but overall, the trend line continues in terms of the strength that we’ve seen there. When I zoom out and I think we talk a lot about diversification in this company, right? We talk about product categories, geographies, species, et cetera. I do think alternative channels also presents another level of diversification. We’re certainly positioned well to meet the consumer wherever their channel of choice is and that includes in the clinic and when products move from the clinic to these alternative channels, we’re positioned to capitalize on those, as well. So I think any move by any party, whether that’s Amazon or anyone else, is going to continue to give more choices to the consumer and our products are available to them to really drive that. And I think from an economics perspective we talked about on this call before, they are neutral to positive versus the overall. So, this is another area that we’re well positioned to continue to capitalize on in terms of where our products are.

And I think that we’ll also continue to grow the compliance for most of our key products. And we’ve got significant percentage of our sales currently for both Apoquel and Simparica Trio over 40% of both in the retail channel. So, I think, Amazon is just one more entrant there.

We’ll hear next from Brandon Vazquez with William Blair. Please go ahead.

Hey everyone. Thanks for taking the question. Kristin, you made a comment about, on the Librela side that maybe consumer sentiment or consumer spending was weighing a little bit maybe on compliance. Can you just talk a little bit about what you guys are seeing through April given kind of consumer sentiments rolling over a little bit, not just in Librela, but just the broader portfolio, are you seeing meaningful changes in compliance across the board or not and just kind of the feeling as we’re going through the second quarter. And then one quick model follow-up question. Wetteny, can you just talk about what price and mix - price and volume expectations are for the rest of the year, as well? Thanks.

Sure. Yeah, I think what we talked about in, our prepared remarks is obviously adoption has been more gradual as you look at sort of the OA pain market. And honestly, some of the more expensive chronic medications right now than we probably initially expected. But look, we’re really encouraged by the foundation that we’re building. We are starting to see in small pockets a more measured approach to managing chronic conditions. I think consumers are making choices that reflect sort of broader consumer trends. But I think what’s great about our portfolio is how broad it is across so many different categories. So, if maybe the most expensive, we also you can look at it in Apoquel, if you’re looking at the derm space. And we’re continuing to see incredibly strong growth right now in wellness. So, as we always say, we see the animal health industry as incredibly durable and recession resistant obviously, we’re not recession proof. And I think what really sets Zoetis apart in this is that, we’re more resilient than the industry given the innovation that we bring to market. We have really disruptive products that meet unmet medical needs and if you look at a growing global population, whether that’s on the food side or in the companion animal side, I think, Zoetis has always weathered these better than others and we believe we’ll continue to do so. Wetteny, do you want to take the second question?

Sure. Look, up price and volume mix is consistent with how we saw them coming into the year and I’ll remind you of a few points here. In 2024, we saw strong volume growth, particularly across our key franchises even as we saw price elevated the last couple of years to the tune of 5% to 6%. We came into this year saying we expect price to be above our historical 2% to 3%, but below those levels from the last couple of years and you saw that play out in the first quarter. Our volume growth out of the 9% organic operational growth was 5% volume and 4% price. I would say the direction of travel for the rest of the year would be consistent in terms of that mix. And one last note is last year we saw higher contributions from our hyperinflationary markets, particularly when you think about livestock in international, where we’re seeing much less of that though we’re seeing some in the first half in the first quarter here much less of that this year versus what we saw last year.

We’ll turn now to Chris Schott with JPMorgan. Please go ahead.

Great. Thanks so much for the questions. Maybe just starting off on derm. Can you just remind us of your latest expectations for Merck’s entrance into the market? What’s kind of reflected in guidance on that? And maybe bigger picture on Apoquel, what percent of the market is chewable at this point and how important is that, I guess, in terms of kind of protecting the franchise competitively? My second question, obviously, a very solid start to the year. I know you don’t give quarterly guidance, but just anything notable we should be watching in terms of quarterly gating as we think about the rest of the year from here? Thanks so much.

Sure. I’ll take I’ll take this and see if, Kristin wants to add to it. So when you look at our guidance today, consistent with February, we put a number of scenarios around the timing of competitive entrants, as well as any short-term, promotional activities that they might have. This does not take away from our long-term view in terms of the opportunity to continue to expand these markets and our confidence that we will continue to drive growth in those, particularly given our first mover advantage. So I want to make sure that is really well understood that our consideration is more short-term implications around promotions and not long-term confidence that we continue to have in those. On Apoquel, particularly, in terms of chewable conversion, if you look at the US, we exited the first quarter around 31% in the aggregate, a little bit higher in the vet clinics and so forth. If you look at International, we’re seeing about 50% conversion across international, but in Europe, it’s actually about 57%. So we’ll continue to see that climb, in terms of our position and last thing I’ll say is coming into a year ago with the launch of chew, we would have anticipated, as we said before, a higher conversion of chew, but I think it’s the stickiness ofApoquel, particularly when you think about the satisfaction levels among vets and pet owners, ownership, et cetera, that is actually driving the conversion rate to be lower than we would have said and I think that’s a good signal for us as we prepare for competition and then of course, longer term in terms of expanding the market.

We’ll go now to Navann Ty with BNP Paribas. Please go ahead.

Hi. Thanks for taking my question. One on Librela. Do you expect to pivot back to accessing the moderate population in the US at some point? And a follow-up on the FDA, could you expect the FDA headcount reduction to impact your competitors’ time line in derms? And finally, can you discuss the new FINTEP-one indication for Simparica Trio versus Elanco’s Credelio and Quattro? Thank you.

Sure. I’ll start with your last one. Yes, we did get approval for the, prevention of flea tapeworm. As we said before, this is we didn’t see that as critically important, obviously, we’ve mentioned this previously. This is just a nice incremental. It certainly, makes it very little differentiation between us and others. But we as we said before, we don’t see this as a major driver. We didn’t think it was a major issue before. With regards to your question on Librela and the shift to moderate patients, that’s obviously a key part of our focus right now and is consistent with all the different levers that we’re really focused on right now on making sure we expand medical education, bringing in the international KOLs, et cetera is moving into that. And your last question was on the FDA and the impacts on either competitors or long-acting. As I said, we have not experienced any delays at the FDA. We would think others would share the same view at this point. I obviously can’t speak for them. So we’re not expecting any issues with the FDA at the moment based on what we know today to be slowing down ours or anyone else’s pipeline.

We’ll go next to Steve Scala with TD Cowen. Please go ahead.

Hi, good morning. This is Chris on for Steve. Thanks for taking our question. We have two just on tariffs. First, it seems like the Trump Administration is pursuing pharmaceutical tariffs under a Section 232 National Security Claim. Based on your interactions with Washington on animal health products viewed as critical to US national security, and what’s the likelihood that US pet products could be excluded, from broader sector tariffs? Thank you.

Sure. Our team here and me personally spent a lot of time in DC on the issue of the 232 sec toral tariffs on pharmaceuticals. What we’ve advocated for and have had a great audience for is, what they’re trying to solve is not the problem that we see in animal health and certainly not Zoetis’ problem. I actually said, if you want to be the poster child, I think Zoetis is it’s. 60% of our total manufacturing is in The United States. 75% of what we sell in the United States, we make in the United States and we are a net exporter. So in the sense of the desire for security and pharmaceuticals in the United States, I don’t really think that animal health or Zoetis is a challenge. We’ve shared this point of view with a number of people. I think it’s too early to tell, which is why we were quite clear, in the guidance that this obviously only included currently enacted tariffs. I would definitely not want to presume where they will ultimately cut out on it, but I think we have a very strong argument and we’ve been spending a lot of time making sure they understand the differences between animal health and human health and where our manufacturing is. Importantly, we’ve made the case of where our intellectual property is, which is also in the United States and where the vast majority of our R&D dollars are, which are also in the United States. So, I think we’ve had a good audience, but I wouldn’t presume to, predict what the administration will do here.

We’ll turn now to Daniel Clark with Leerink Partners. Please go ahead.

Great. Thank you. Just another question on Librela. When you think about how the launches progress versus your initial expectations, is it really on the patient start side or on the months on therapy side that you’ve seen like, a bigger divergence from where you thought performance was going to be? That’s my question. Thank you.

So, look, I think if you look at the performance of Librela, first of all, just to see just how much interest there is in terms of vet looking for solutions for pain, you saw 86% penetration across clinics. And we continue to see very strong satisfaction levels for vets who are using the product. So I think that really is a great foundation for us. We’ve seen a transition into more moderate cases and patient starts and expansion of the market with those that were previously not treated by NSAIDs in Europe and that continues to be our focus in the US through education of veterinarians and pet owners in terms of the long-term impacts of OA pain over time, which I think are important to note and will continue to drive those. So, as we said, the uptick hasn’t been as fast on the ramp as we like, but I think the foundation is strong and certainly, undoubtedly, the size of the opportunity remains very vast.

As there are no further questions at this time, I’d like to turn the floor back over to management for any additional or closing comments.

Thank you. As always, I want to thank everyone for joining today for your questions and importantly for your continued interest in Zoetis. Just to summarize, we have the industry’s most diverse and durable portfolio. And animal health is essential and both the industry and Zoetis have proven to be resilient across many different economic cycles and all different types of market conditions and that’s why we continue to see steady sustainable demand for our products across species and geographies. And as we look ahead, we remain focused on executing our strategy with discipline, while staying agile and responsive to the dynamic world around us. We strongly believe that with our innovation, our global reach and our dedicated teams, we are confident in our ability to continue to lead this industry forward. So thanks. Thanks everyone for joining us and have a great day.

Thank you. Once again ladies and gentlemen, that will conclude today’s Zoetis event. Thank you for your participation. You may disconnect at this time and have a wonderful rest of your day.